Lv41
410 积分 2022-09-13 加入
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a randomised, phase 3 trial
55分钟前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial
55分钟前
已完结
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results of the Phase II COALITION Study
55分钟前
已完结
奥布替尼联合R-CHOP方案治疗初治高危伴结外累及的非生发中心起源的弥漫大B细胞淋巴瘤的临床研究
1小时前
已完结
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma (ZUMA-12)
1小时前
已完结
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
1小时前
已完结
CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy
1小时前
已完结
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Patients With Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study
1小时前
已完结
Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma: an Asia subpopulation analysis from the phase 3 POLARIX trial
1小时前
求助中
Current Treatment Strategies for Diffuse Tenosynovial Giant Cell Tumor: A Review of the Literature
2个月前
已完结
皖公网安备34019202002308
